Arcus Biosciences Inc (RCUS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $2.51B
Last updated: Nov 17, 2026 at 11:06 AM ET
Arcus Biosciences Inc (RCUS) Stock Forecast
Analysts expect Arcus Biosciences (RCUS) to earn -$3.48 per share in the fiscal year ending Dec 31, 2026, on revenue of $72.40M. Of 15 analysts, 13 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 87% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 6.7% |
| Buy | 12 | 80.0% |
| Hold | 2 | 13.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 36.4%.
- Fiscal year ending Dec 31, 2026
- -$3.48
- EPS consensus, revenue $72.40M
- Fiscal year ending Dec 31, 2027
- -$3.09
- EPS consensus, revenue $46.03M
- Next report
- Feb 23, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.48 | -$3.75 to -$3.03 | 9 | $72.40M | $67.00M to $81.50M | 13 |
| Dec 31, 2027 | -$3.09 | -$4.07 to -$2.16 | 10 | $46.03M | N/A | 11 |
Quarterly Estimates
The EPS consensus falls from -$0.86 for the quarter ending Dec 31, 2026 to -$0.88 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.86 | -$0.98 to -$0.74 | 16 | $6.72M | N/A | 15 |
| Mar 31, 2027 | -$0.88 | -$1.00 to -$0.78 | 5 | $6.03M | N/A | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 3 | 3 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.65.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.48 | -$3.52 | -$3.48 | -$3.53 | -$3.65 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.09 | -$3.12 | -$3.27 | -$3.34 | -$3.25 | N/A |
| Quarter ending Mar 31, 2027 | -$0.88 | -$0.89 | -$0.92 | -$0.96 | -$0.96 | N/A |
Frequently Asked Questions About RCUS
What is the RCUS stock forecast?
Consensus analyst estimates put Arcus Biosciences's EPS at -$3.48 for the fiscal year ending Dec 31, 2026, on revenue of $72.40M. The consensus rating from 15 analysts is Buy.
How do analysts rate RCUS stock?
Of 15 analysts covering Arcus Biosciences, 1 rates it Strong Buy, 12 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RCUS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.48, with estimates from -$3.75 to -$3.03 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.09, with estimates from -$4.07 to -$2.16 from 10 analysts.
What revenue do analysts expect from Arcus Biosciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $72.40M, with estimates from $67.00M to $81.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $46.03M.
How many analysts cover RCUS?
15 analysts rate Arcus Biosciences stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RCUS pages: Overview, Earnings, Forecast, Financials, Competitors